Genotype, serum level of HCV-RNA and response to interferon-alpha treatment in patients with chronic hepatitis C

Neth J Med. 1995 Dec;47(6):265-71. doi: 10.1016/0300-2977(95)00101-8.

Abstract

Objective: Since only a small proportion of patients with chronic hepatitis C benefit from interferon therapy, we assessed the viral factors such as HCV genotype and the level of viraemia for prediction of interferon response.

Methods: HCV genotype and serum levels of HCV-RNA were determined in 24 patients before, during and after interferon treatment.

Results: Pre-treatment serum levels of HCV-RNA were significantly lower in patients with normalization of serum ALT and disappearance of serum HCV-RNA upon therapy than in patients with persistent abnormal ALT and/or serum HCV-RNA positivity. Sole infection with HCV genotype 1b was associated with a significantly higher pre-treatment serum HCV-RNA level than infection with genotype other than 1b or mixed types.

Conclusions: HCV genotype and pre-treatment serum HCV-RNA levels are indeed important predictors for response to interferon treatment in patients with chronic hepatitis C.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use*
  • Chronic Disease
  • Drug Monitoring
  • Female
  • Genotype
  • Hepacivirus / classification
  • Hepacivirus / genetics*
  • Hepatitis C / blood
  • Hepatitis C / therapy*
  • Hepatitis C / virology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • RNA, Viral / blood*
  • Recombinant Proteins
  • Serotyping

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Alanine Transaminase